From SA: Key events next week - healthcare Feb
Post# of 36566
(Total Views: 242)
Posted On: 02/22/2019 8:33:17 AM
From SA:
Key events next week - healthcare
Feb. 22, 2019 7:42 AM ET|About: Aldeyra Therapeutics, ... (ALDX)|By: Douglas W. House, SA News Editor
Noteworthy events during the week of February 24 - March 2 for healthcare investors.
MONDAY (2/25): Global NASH Congress, London (2 days).
Huntington's Disease Conference, Palm Springs, CA (4 days). UniQure (NASDAQ:QURE): Gene therapy for HD.
FDA action date for Bausch Health (NYSE:BHC) unit Bausch + Lomb's loteprednol ophthalmic gel 0.38% for the treatment of postoperative pain and inflammation following eye surgery.
CAR-TCR Summit Europe, London (3 days): Ziopharm Oncology (NASDAQ:ZIOP): Non-viral gene transfer to commercialize T-cell therapies (CEO presentation).
TUESDAY (2/26): Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction Winter Meeting, Miami, FL (5 days).
CytomX Therapeutics (NASDAQ:CTMX): R&D Day, NYC.
Generex Biotechnology (OTCQB:GNBT): Conference call (11 am ET) to update investors on strategy and operations.
Equillium (NASDAQ:EQ): Business update conference call.
THURSDAY (2/28): ASCO-SITC Symposium, San Francisco (3 days). Heat Biologics (NASDAQ:HTBX): Phase 2 data on HS-110 + Opdivo in advanced NSCLC. Compugen (NASDAQ:CGEN): Phase 1 trial design for COM701 in solid tumors. Iovance Biotherapeutics (NASDAQ:IOVA): TIL therapy in melanoma.
Nu Skin Enterprises (NYSE:NUS) Investor Day, Provo, UT.
Aldeyra Therapeutics (NASDAQ:ALDX): R&D Day, NYC.
CHMP action date for review of Portola Pharmaceuticals' (NASDAQ
TLA) marketing application for Ondexxya (andexanet alfa).
ACTRIMS Annual Meeting, Dallas, TX (3 days). TG Therapeutics (NASDAQ:TGTX): Phase 2 data on ublituximab in relapsing forms of multiple sclerosis.
FRIDAY (3/1): American Academy of Dermatology Annual Meeting, Washington, DC (5 days). Athenex (NASDAQ:ATNX): Data from two Phase 2 trials of KX2-391 ointment for actinic keratosis. XBiotech (NASDAQ:XBIT): Bermekimab in atopic dermatitis. Concert Pharmaceuticals (NASDAQ:CNCE): Phase 2 data on CTP-543 in alopecia areata.
See all
Key events next week - healthcare
Feb. 22, 2019 7:42 AM ET|About: Aldeyra Therapeutics, ... (ALDX)|By: Douglas W. House, SA News Editor
Noteworthy events during the week of February 24 - March 2 for healthcare investors.
MONDAY (2/25): Global NASH Congress, London (2 days).
Huntington's Disease Conference, Palm Springs, CA (4 days). UniQure (NASDAQ:QURE): Gene therapy for HD.
FDA action date for Bausch Health (NYSE:BHC) unit Bausch + Lomb's loteprednol ophthalmic gel 0.38% for the treatment of postoperative pain and inflammation following eye surgery.
CAR-TCR Summit Europe, London (3 days): Ziopharm Oncology (NASDAQ:ZIOP): Non-viral gene transfer to commercialize T-cell therapies (CEO presentation).
TUESDAY (2/26): Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction Winter Meeting, Miami, FL (5 days).
CytomX Therapeutics (NASDAQ:CTMX): R&D Day, NYC.
Generex Biotechnology (OTCQB:GNBT): Conference call (11 am ET) to update investors on strategy and operations.
Equillium (NASDAQ:EQ): Business update conference call.
THURSDAY (2/28): ASCO-SITC Symposium, San Francisco (3 days). Heat Biologics (NASDAQ:HTBX): Phase 2 data on HS-110 + Opdivo in advanced NSCLC. Compugen (NASDAQ:CGEN): Phase 1 trial design for COM701 in solid tumors. Iovance Biotherapeutics (NASDAQ:IOVA): TIL therapy in melanoma.
Nu Skin Enterprises (NYSE:NUS) Investor Day, Provo, UT.
Aldeyra Therapeutics (NASDAQ:ALDX): R&D Day, NYC.
CHMP action date for review of Portola Pharmaceuticals' (NASDAQ
TLA) marketing application for Ondexxya (andexanet alfa). ACTRIMS Annual Meeting, Dallas, TX (3 days). TG Therapeutics (NASDAQ:TGTX): Phase 2 data on ublituximab in relapsing forms of multiple sclerosis.
FRIDAY (3/1): American Academy of Dermatology Annual Meeting, Washington, DC (5 days). Athenex (NASDAQ:ATNX): Data from two Phase 2 trials of KX2-391 ointment for actinic keratosis. XBiotech (NASDAQ:XBIT): Bermekimab in atopic dermatitis. Concert Pharmaceuticals (NASDAQ:CNCE): Phase 2 data on CTP-543 in alopecia areata.
See all
(0)
(0)